Posts by Marcela V. Maus, MD, PhD
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
CAR T-cell Therapy Feasible for Active Secondary CNS Lymphoma
Central nervous system involvement does not appear to be a risk factor for severe neurotoxicity with CD19-directed CAR T-cell therapy.
-
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
Biography
Marcela Maus, MD, PhD, is the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center. Dr. Maus was recently recruited to the Massachusetts General Hospital Cancer Center to lead a new program in Cellular Immunotherapy. She is a member of the Center for Cancer Immunology and the Department of Medicine at the MGH, and she is an Assistant Professor at Harvard Medical School. Her laboratory is generating new forms of chimeric antigen receptors directed to new targets and bringing them to the clinical setting to treat patients with hematologic malignancies and solid tumors.
Dr. Maus trained in internal medicine at U. Penn and at Memorial Sloan Kettering as a hematologist and medical oncologist. Her post-doctoral works was with Michel Sadelain and Carl June, where she focused on pre-clinical development and correlative studies relevant to T cell immunotherapies, designing early-phase trials of T cell therapies for multiple myeloma, chronic lymphocytic leukemia, and glioblastoma.